157 related articles for article (PubMed ID: 36465710)
21. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
23. Ovarian masses: changing clinico histopathological trends.
Sharadha S; Sridevi TA; Renukadevi TK; Gowri R; Binayak D; Indra V
J Obstet Gynaecol India; 2015 Feb; 65(1):34-8. PubMed ID: 25737620
[TBL] [Abstract][Full Text] [Related]
24. Aurora-A kinase is differentially expressed in the nucleus and cytoplasm in normal Müllerian epithelium and benign, borderline and malignant serous ovarian neoplasms.
Alkhateeb KJ; Crane JE; Sak M; Jorgensen CJ; O'Donnell JP; Zumbar CT; Wozniak JA; Salazar CR; Parwani AV; Lehman NL
Diagn Pathol; 2021 Oct; 16(1):98. PubMed ID: 34706741
[TBL] [Abstract][Full Text] [Related]
25. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
Giurgea NL; Pitrop M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
[TBL] [Abstract][Full Text] [Related]
26. Clinicomorphological Spectrum of Ovarian Cystic Lesions.
Dhakal R; Makaju R; Bastakoti R
Kathmandu Univ Med J (KUMJ); 2016; 14(53):13-16. PubMed ID: 27892434
[TBL] [Abstract][Full Text] [Related]
27. Age distribution and types of breast lesions among Afghan women diagnosed by fine needle aspiration cytology (FNAC) at a tertiary care centre in Afghanistan: a descriptive cross-sectional study.
Saadaat R; Abdul-Ghafar J; Haidary AM; Rahmani S; Atta N
BMJ Open; 2020 Sep; 10(9):e037513. PubMed ID: 32873674
[TBL] [Abstract][Full Text] [Related]
28. Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation.
Taylor EC; Irshaid L; Mathur M
Radiographics; 2021; 41(1):289-315. PubMed ID: 33186060
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
30. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal.
Prat J
Adv Anat Pathol; 1999 Sep; 6(5):247-74. PubMed ID: 10472378
[TBL] [Abstract][Full Text] [Related]
31. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
32. Clinico-histopathological analysis of neoplastic and non-neoplastic lesions of the ovary: a 3-year prospective study in dhule, north maharashtra, India.
S N K; N V D; P N D; D B N; K H S
J Clin Diagn Res; 2014 Aug; 8(8):FC04-7. PubMed ID: 25302198
[TBL] [Abstract][Full Text] [Related]
33. A pathological and clinical study of 706 primary tumours of the ovary in the largest tertiary hospital in Ghana.
Akakpo PK; Derkyi-Kwarteng L; Gyasi RK; Quayson SE; Naporo S; Anim JT
BMC Womens Health; 2017 Apr; 17(1):34. PubMed ID: 28415994
[TBL] [Abstract][Full Text] [Related]
34. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
35. The Histopathological Patterns of Ovarian Neoplasms in Different Age Groups: A Retrospective Study in a Tertiary Care Center.
Farag NH; Alsaggaf ZH; Bamardouf NO; Khesfaty DM; Fatani MM; Alghamdi MK; Saharti SN
Cureus; 2022 Dec; 14(12):e33092. PubMed ID: 36721593
[TBL] [Abstract][Full Text] [Related]
36. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa?
Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT
Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429
[TBL] [Abstract][Full Text] [Related]
37. Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report.
Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Piyawong W; Himakhun W; Bhamarapravatana K
J Med Assoc Thai; 2016 Jul; 99 Suppl 4():S281-6. PubMed ID: 29927186
[TBL] [Abstract][Full Text] [Related]
38. Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature.
Idrees R; Din NU; Siddique S; Fatima S; Abdul-Ghafar J; Ahmad Z
J Ovarian Res; 2021 Mar; 14(1):47. PubMed ID: 33736662
[TBL] [Abstract][Full Text] [Related]
39. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.
Kabawat SE; Bast RC; Welch WR; Knapp RC; Colvin RB
Am J Clin Pathol; 1983 Jan; 79(1):98-104. PubMed ID: 6336888
[TBL] [Abstract][Full Text] [Related]
40. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.
Puls LE; Powell DE; DePriest PD; Gallion HH; Hunter JE; Kryscio RJ; van Nagell JR
Gynecol Oncol; 1992 Oct; 47(1):53-7. PubMed ID: 1427402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
